2971704-85-3

Uses

RXFP2 agonist 2 is a selective, orally active and allosteric RXFP2 agonist with an EC50 value of 0.38 μM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis[1].

in vivo

RXFP2 agonist 2 (10 mg/kg; p.o.; 3 times per week for 8 weeks) promotes bone formation in female mice^[1].

Animal Model:	8-week-old WT C57BL/6?J female mice^[1]
Dosage:	3 mg/kg for i.v.; 10 mg/kg for p.o.
Administration:	I.v. or p.o.
Result:	Exhibited a half-life of between 4-6.5?h depending on the route of administration, with no accumulation at 10?mg/kg, and oral bioavailability around 25-31%.

Animal Model:	8-week-old WT C57BL/6?J female mice^[1]
Dosage:	10 mg/kg
Administration:	P.o.; 3 times per week for 8 weeks
Result:	Increased bone formation in mouse with significantly increased in Tb.N and Tb.Th, and increased BV/TV and decreased Tb.Sp.

References

[1] Esteban-Lopez M, et al. Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2. Commun Biol. 2022 Nov 4;5(1):1183. DOI:10.1038/s42003-022-04143-9

Hazard Information

Uses

in vivo

References

Related Products